Skip to main content

Table 1 Characteristics of HCC patients

From: Development of nomogram models of inflammatory markers based on clinical database to predict prognosis for hepatocellular carcinoma after surgical resection

Variables Median (range)/Mean±SD/N (%)
Gender(male/female) 298(82.8%)/62(17.2%)
Age,years 59.2±10.9
HBV(yes/no) 311(86.4%)/49(13.6%)
Anti-HBV(yes/no) 129(35.8%)/231(64.2%)
Family history of HCC 16(4.4%)/344(95.6%)
Hypertension(yes/no) 101(28.1%)/259(71.9%)
Diabetes(yes/no) 47(13.1%)/313(86.9%)
ALT, U/L (≤50/>50) 287(79.7%)/73(20.3%)
ALP, U/L (≤125/>125) 286(79.4%)/74(20.6%)
GGT, U/L (≤60/>60) 204(56.7%)/156(43.3%)
PT, seconds (≤13/>13) 303(84.2%)/57(15.8%)
ALBI(≤-2.60/ -2.60 to -1.39/>-1.39) 236(65.6%)/120(33.3%)/4(1.1%)
DB, umol/l (≤8/>8) 297(82.5%)/63(17.5%)
INR(≤1/>1) 85(23.6%)/275(76.4%)
AFP,ng/mL (≤20/20 to 400/>400) 167(46.4%)/96(26.7%)/97(26.9%)
PNI 48.9(26.5,73.3)
APRI 0.22(0.04,4.58)
ALRI 21.70(5.67,514.62)
ANRI 10.72(1.51,209.06)
SII 296.59(50.80,7846.67)
NLR 2.00(0.40,73.33)
PLR 102.18(30.91,500.00)
MLR 0.29(0.12,5.17)
SIRI 0.85(0.21,75.43)
Pathological differentiation(well/moderate/poor) 167(46.4%)/96(26.7%)/97(26.9%)
MVI(yes/no) 180(50%)/180(50%)
Cirrhosis(yes/no) 173(48.1%)/187(51.9%)
Number of tumours(solitary/multiple) 290(80.6%)/70(19.4%)
Tumour diameter, cm 4.98±3.07
Tumour capsule(yes/no) 299(83.1%)/61(16.9%)
PVTT(yes/no) 30(8.3%)/330(91.7%)
Child-Pugh grade (A/B) 354(98.3%)/6(1.7%)
AJCC T stage (I - II /III - IV) 280(77.8%)/80(22.2%)
  1. Abbreviations: HBV Hepatitis B Virus, ALT alanine aminotransferase, ALPalkaline phosphatase, GGT γ-glutamyl transpeptidase, PT prothrombin time, DB direct bilirubin, INR international normalized ratio, AFP alpha-fetoprotein, MVI microvascular invasion, PVTT portal vein tumour thrombosis